BioOnly

$ctmx there will be a big upside move coming… fund is buying, up in big down day today with larger volume and block trades, the one short is about to be done…. $xbi.

$ctmx. More than 1M shares traded again after market- fund buying……. Ready for the move, back to $6-8 soon. $xbi

$ctmx. 1m block shares just traded after market, Institute/fund buying, that one short will be toasted. And thanks for all these cheap shares. $xbi

@STL_Biotech The signal seems consistent at each read, with safety either consistent or trending better as they implement prophylaxis. Do you feel like its a viable drug? Does share price reflect uncertainty or lack of catalysts? Data on remaining p1 pts this summer? $CTMX

$ctmx. One short is working really hard to keep the price down, eventually funds will see the potential of the company and shorts will pay. Not too long….. $xbi

$SNDX (L) Good Chat thread on M&A comps in the oncology space given today's $TERN news $INCY clearly needs the revenues Niktimvo + Revuforj could provide, just a matter of timing & whether Syndax gets too big for them Putting on my skeptical hat, I think it goes for $35 to $40 if bought out today (if shareholders get screwed). Reasonable would be $45 -$50 If we wait for IPF and frontline AML data (ven/aza triplet), rises to $60+ (if high MRD rate holds up along with manageable AEs)

Keep adding

$ctmx. Don’t think shorts will be able to hold down for longer, will back to $6-8 in couple weeks. $xbi

$CTMX

Jefferies reiterated $CTMX Buy/$16, and said: We spoke w/ mgmt following recent Ph1a topline to clarify several outstanding questions. $PFE MRK RHHBY DSNKY $ABBV Jefferies added: Varseta-M (masked EpCAM/Topo1 ADC) showed impressive results in late-line mCRC, with active dose narrowed to 8.6/ 10 mg/kg and updated dual Gl prophylaxis in dose optimization to select pivotal dose, with full package update (pivotal dose/ plan with supporting data) by YE26. With recent financing, we see good entry point at current value and expect stock move up into YE... While we all love to see more data, we think Varseta-M has been meaningfully derisked in a few ways including the absence of EpCAM-class toxicities in an expanded ~80 patient dataset and durability holding in a difficult 4L+ mCRC population (Topline, Debates). Narrative has shifted from "do we have a drug?" to "how can we best take on Varesta-M across the continuum of mCRC plus into other solid tumors?" Mgmt was candid that work remains (diarrhea AE mitigation and dose fine-tuning as active workstreams), but emphasized they had converged on doses that work, had raised capital for further development, and were prioritizing execution from here. We also note mgmt's continued effort to remain transparent and engaged w/ investors, mgmt booked back to back lately, reporting ~60+ meetings since our recent catch-up last week following topline results. Stock drivers we see from here: (1) incremental efficacy/ durability updates at chosen go-fwd dose; (2) evidence that mandated dual prophylaxis improves tolerability/ deliverability w/o eroding exposure/activity; (3) clarity on Gl toxicity mechanism/ algorithms to support pivotal design; (4) timing and design of a pivotal path initiating likely 1H27.

$ctmx. Lifetime buying opportunity. $xbi

$ctmx Shorts are very active for the past two days (even with some fake articles)- thanks for them I were able to add under $5, eventually people will realize the great p1 data, and will back to $8-10. $xbi

$sndx. Take over target….. $xbi

$sndx. Short squeeze……. $28. $xbi

$ctmx. Shorts will be squeezed, no downside….$xbi

$SNDX valuation, analyst revenue estimates & related multiples v $DAWN M&A exit valuation If DAWN now trades for 1.03X 5-year consensus, would SNDX command higher multiples in a hypothetical M&A exit? The attached are questions. This is not investment advice $INCY $XBI $IBB

$ctmx. Just one big block traded 4m shares……. $xbi. Funds buying before the data next Monday.